Cancer is considered as the second leading cause of death worldwide. Constant efforts are made worldwide to find effective and selective treatments for cancer, one of the emerging targeted therapies is kinase trargeting. Kinases phosphorylate proteins which later causes further signal transduction. Recent research revealed that these kinases by themselves or if they go under certain mutations can lead to dysregulated cellular prolefration thus causing cancer intiation and/or metastasis. For this thesis we focused on two main kinases, the JNK3 and FMS kinases which were found to be inhibited by two scaffolds triarylpyrazole and pyridopyridine respectively. In the first part of the project, the design, synthesis, and biological activities of a new series of pyrazole derivatives are reported. The target compounds 1a-w were initially investigated against NCI-60 cancer cell lines. Compounds 1f, 1h, 1k, and 1v exerted the highest antiproliferative activity over the studied panel of cancer cell lines. Compound 1f showed the most potent activity, and it is more potent than sorafenib in 29 cancer cell lines of different types and more potent than SP600125 against all the tested cell lines. It also exerted sub micromolar IC50 values (0.54-0.98 µM) against nine cell lines. Moreover, the 23 target compounds were tested against Hep3B and HepG2 hepatocellular carcinoma cell lines, of which compounds 1b, 1c, and 1h showed the strongest antiproliferative activity. The most potent anticancer compounds (1b, 1c, 1f, and 1h) demonstrated a high selectivity towards cancer cells vis-à-vis normal cells. Compounds 1f and 1h induced apoptosis and mild necrosis upon testing against RPMI-8226 leukemia cells. Kinase profiling of this series led to the discovery of two potent and selective JNK3 inhibitors, compounds 1c and 1f with an IC50 values of 99.0 and 97.4 nM, respectively. Both compounds showed a good inhibitory effect against JNK3 kinase in the whole-cell NanoBRET assay. This finding was further suppor